Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

Completed · Phase 4

Conditions studied: Glaucoma, Ocular Hypertension

In brief

To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

Key facts

Study ID
NCT02167035
Run by
Cornerstone Health Care, PA
People needed
43
Starts
2014-08-01
Expected to finish
2018-03-01
Last updated by the study team
2018-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.